EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Inhibition of OATP1B1 /3 Rather Than UGT1A1 May Be the Major Cause of the Bilirubin Elevation After Atazanavir Administration

Jin Dong iD, Pradeep Sharma iD, Rasha Emara iD, Derek Cheung iD, Weifeng Tang iD, Diansong Zhou iD, David W Boulton iD, Mats Någård iD, Miki S Park iD

Clinical Pharmacology & Therapeutics · 2025

DOI: 10.1002/cpt.3529 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Pharmacology & Therapeutics, 2025. Verfasst von Jin Dong und 8 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Pharmacology and Quantitative Pharmacology, Clinical Pharmacology and Safety Sciences, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, Ma…. Hauptthemen laut MEDLINE: Glucuronosyltransferase, Atazanavir Sulfate, Bilirubin, Organic Anion Transporters. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Atazanavir has been reported to increase total serum bilirubin level up to ninefold. It is widely believed that the observed total bilirubin elevation is primarily due to UGT1A1 inhibition. However, UGT enzymes are well‐known as a low‐affinity and high‐capacity system, and the observed drug–drug interaction mediated by UGTs is usually less than twofold. There were discrepancies in the explanation of total bilirubin elevation due to UGT1A1 inhibition alone, suggesting the contribution of other mechanism(s) to the interaction. As atazanavir is a potent OATP1B1/3 inhibitor and the hepatic uptake of both unconjugated and conjugated bilirubin are mediated by OATP1B1/3, these transporters could be involved in the bilirubin–atazanavir interaction. To better understand the roles of UGT1A1 and OATP1B1/3 in this interaction, it would be useful to characterize the contribution of each individual pathway to the interaction. As multiple compounds, pathways, and potentially UGT1A1 polymorphism are involved, a thorough physiologically‐based pharmacokinetic (PBPK) analysis was utilized to integrate the information from various relevant in vitro and clinical studies to quantitatively estimate the contribution of UGT1A1 and OATP1B1/3 inhibition to the interaction between bilirubin and atazanavir. The PBPK analysis indicated that UGT1A1 inhibition plays a modest role in bilirubin and atazanavir interaction contributing less than 33%. The results also suggested that unconjugated bilirubin is less sensitive than raltegravir upon UGT1A1 inhibition, therefore, unconjugated bilirubin may not be a useful endogenous biomarker for UGT1A1 inhibition. The analysis demonstrated that the metabolism of unconjugated bilirubin shares common features of other UGT enzyme‐mediated reactions.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

GlucuronosyltransferaseAtazanavir SulfateBilirubinOrganic Anion TransportersOrganic Anion Transporters, Sodium-IndependentHIV Protease InhibitorsPyridinesOligopeptidesHumansLiver-Specific Organic Anion Transporter 1Solute Carrier Organic Anion Transporter Family Member 1B3Drug InteractionsUGT1A1 Enzyme

Substanzen

GlucuronosyltransferaseAtazanavir SulfateBilirubinLiver-Specific Organic Anion Transporter 1Solute Carrier Organic Anion Transporter Family Member 1B3Organic Anion TransportersOrganic Anion Transporters, Sodium-IndependentHIV Protease InhibitorsPyridinesOligopeptides

Autor:innen und Institutionen

  • Clinical Pharmacology and Quantitative Pharmacology, Clinical Pharmacology and Safety Sciences, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, Maryland, USA.
  • Clinical Pharmacology and Quantitative Pharmacology, Clinical Pharmacology and Safety Sciences, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK.
  • Department of Pharmaceutical Sciences, Thomas J. Long School of Pharmacy, University of the Pacific, Stockton, California, USA.
  • Clinical Pharmacology and Quantitative Pharmacology, Clinical Pharmacology and Safety Sciences, BioPharmaceuticals R&D, AstraZeneca, Boston, Massachusetts, USA.

ORCID-Profile: Jin Dong, Pradeep Sharma, Rasha Emara, Derek Cheung, Weifeng Tang, Diansong Zhou, David W Boulton, Mats Någård, Miki S Park

Zitieren

APA

Dong, J., Sharma, P., Emara, R., Cheung, D., Tang, W., Zhou, D., Boulton, D. W., Någård, M., & Park, M. S. (2025). Inhibition of OATP1B1 /3 Rather Than UGT1A1 May Be the Major Cause of the Bilirubin Elevation After Atazanavir Administration. Clinical Pharmacology & Therapeutics. https://doi.org/10.1002/cpt.3529

Vancouver

Dong J, Sharma P, Emara R, Cheung D, Tang W, Zhou D, et al. Inhibition of OATP1B1 /3 Rather Than UGT1A1 May Be the Major Cause of the Bilirubin Elevation After Atazanavir Administration. Clinical Pharmacology & Therapeutics. 2025. doi:10.1002/cpt.3529

BibTeX
@article{Dong2025,
  author = {Dong, Jin and Sharma, Pradeep and Emara, Rasha and Cheung, Derek and Tang, Weifeng and Zhou, Diansong and Boulton, David W and Någård, Mats and Park, Miki S},
  title = {Inhibition of OATP1B1 /3 Rather Than UGT1A1 May Be the Major Cause of the Bilirubin Elevation After Atazanavir Administration},
  journal = {Clinical Pharmacology & Therapeutics},
  year = {2025},
  doi = {10.1002/cpt.3529}
}
Kostenlos starten →